RxDoctor Payments Data

Kambiz Vahabzadeh, MD

Internal Medicine · West Hollywood, CANPI 1659550473

Payments from drug & device makers

$16,115in general payments, 2019–2025

Across 678 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Vifor Pharma, Inc.$2K
  • AstraZeneca$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • OPKO Pharmaceuticals, LLC$668
  • Fresenius USA Marketing, Inc.$651
  • plus $7K from 38 others

What the payments were for

  • Speaking & faculty fees$1,91812%
  • Food & beverage$13,90586%
  • Education$2922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,115 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$532,684
Medicare patients
881
Services billed
3,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol371$309,044
VeltassaPatiromer Calcium Sorbitex52$55,968
KerendiaFinerenone30$32,493
JardianceEmpagliflozin28$28,745
LokelmaSodium Zirconium Cyclosilicate24$27,379
Tolvaptan11$27,348
VelphoroSucroferric Oxyhydroxide12$21,252
EntrestoSacubitril/Valsartan11$14,327
EliquisApixaban11$11,113
DapagliflozinDapagliflozin Propanediol21$10,810
Paricalcitol130$10,756
Meropenem16$9,466
EdarbiAzilsartan Medoxomil11$8,177
Sevelamer Carbonate49$7,615
VascepaIcosapent Ethyl12$7,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,689$336,423395 claims
BayerKerendia$623$32,49330 claims
Boehringer IngelheimJardiance$507$28,74528 claims
Fresenius USA Marketing, Inc.Velphoro$651$21,25212 claims
NovartisEntresto$336$14,32711 claims
Arbor Pharmaceuticals, Inc.Edarbi$114$8,17711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →